Laboratory Evaluation for Gynecomastia
When gynecomastia is confirmed on physical examination, order the following core laboratory panel: total testosterone (tT), estradiol (E2), luteinizing hormone (LH), human chorionic gonadotropin (hCG), and prolactin (PRL) 1, 2.
Core Laboratory Tests (Order These First)
The basic hormonal workup should include 1, 2:
- Total testosterone (tT) - identifies hypogonadism, present in ~27% of gynecomastia cases 3
- Estradiol (E2) - detects hyperestrogenism and correlates with breast tissue volume 3
- Luteinizing hormone (LH) - differentiates primary from secondary hypogonadism
- Human chorionic gonadotropin (hCG) - screens for testicular germ cell tumors
- Prolactin (PRL) - identifies prolactinomas or medication effects
Additional Tests Based on Clinical Findings
Order these selectively when the core panel or clinical examination suggests specific pathology 1, 2:
- Follicle-stimulating hormone (FSH) - when LH is abnormal or testicular pathology suspected
- Thyroid-stimulating hormone (TSH) and free T4 - if thyroid dysfunction suspected clinically
- Alpha-fetoprotein (AFP) - if testicular mass detected or hCG elevated (germ cell tumor markers)
- Sex hormone-binding globulin (SHBG) - calculate free testosterone; SHBG elevation found even in idiopathic cases 3
- Dehydroepiandrosterone (DHEA) - if adrenal pathology suspected
- Liver function tests - if chronic liver disease suspected (cirrhosis causes gynecomastia)
- Renal function tests - if chronic kidney disease present
Critical Diagnostic Context
Physical examination findings determine the extent of laboratory workup needed 2. The hormonal evaluation reveals underlying pathology in approximately 45-50% of adult gynecomastia cases 2. However, idiopathic gynecomastia still accounts for nearly half (46%) of cases even after complete evaluation 3.
Key Clinical Pearls:
- Always perform testicular ultrasound alongside laboratory testing - palpation alone has low sensitivity for detecting testicular tumors, which can present with gynecomastia 2
- Don't stop at one obvious cause - multiple etiologies can coexist 4
- Hypogonadism is common - found in 27% of gynecomastia patients and often presents with elevated BMI 3
- SHBG elevation is significant - even in idiopathic cases, SHBG levels are elevated compared to controls, suggesting subtle hormonal alterations contribute to breast enlargement 3
Important Caveats:
The presence of an apparent cause (like medication use) should not preclude detailed laboratory investigation 2. Gynecomastia may be the presenting symptom leading to diagnosis of hypogonadism in over 40% of affected patients 5, making thorough hormonal evaluation clinically valuable beyond just explaining the breast enlargement.
Metabolic screening is also warranted - 53% of gynecomastia patients have metabolic syndrome, with the highest prevalence in medication-induced and hypogonadal cases 5. The long-standing hormonal imbalance may negatively impact metabolic health, justifying screening for cardiovascular risk factors.